Article
Arguably, the biggest advance in skin cancer therapy is the development of topical medications.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Update: FDA Extends Review of Ruxolitinib Cream for Pediatric AD
Derm Dispatch: Advocating for Skin and Nail Health to Spread Melanoma Awareness
Nail Trends That Challenge Clinical Diagnosis
Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor
FDA Approves Dupilumab, First and Only Targeted Medicine for Bullous Pemphigoid
Q&A Part 1: Reviewing the Significance of Lebrikizumab for Patients With Skin of Color, With Anabela Cardoso, MD